TWI781912B - 有效於治療肝毒性及脂肪肝疾病的化合物及其用途 - Google Patents

有效於治療肝毒性及脂肪肝疾病的化合物及其用途 Download PDF

Info

Publication number
TWI781912B
TWI781912B TW105131118A TW105131118A TWI781912B TW I781912 B TWI781912 B TW I781912B TW 105131118 A TW105131118 A TW 105131118A TW 105131118 A TW105131118 A TW 105131118A TW I781912 B TWI781912 B TW I781912B
Authority
TW
Taiwan
Prior art keywords
group
liver
combination
mannitol
pharmaceutically acceptable
Prior art date
Application number
TW105131118A
Other languages
English (en)
Chinese (zh)
Other versions
TW201722897A (zh
Inventor
胡幼圃
石東原
熊正輝
何欣恬
Original Assignee
欣耀生醫股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/078039 external-priority patent/WO2017084234A1/zh
Application filed by 欣耀生醫股份有限公司 filed Critical 欣耀生醫股份有限公司
Publication of TW201722897A publication Critical patent/TW201722897A/zh
Application granted granted Critical
Publication of TWI781912B publication Critical patent/TWI781912B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/21—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
    • C07C51/215—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of saturated hydrocarbyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/42—Glutaric acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TW105131118A 2015-09-24 2016-09-26 有效於治療肝毒性及脂肪肝疾病的化合物及其用途 TWI781912B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562222959P 2015-09-24 2015-09-24
US62/222,959 2015-09-24
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物
WOPCT/CN2016/078039 2016-03-31

Publications (2)

Publication Number Publication Date
TW201722897A TW201722897A (zh) 2017-07-01
TWI781912B true TWI781912B (zh) 2022-11-01

Family

ID=60047309

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105131118A TWI781912B (zh) 2015-09-24 2016-09-26 有效於治療肝毒性及脂肪肝疾病的化合物及其用途

Country Status (20)

Country Link
US (4) US10456371B2 (enExample)
EP (3) EP4609911A3 (enExample)
JP (2) JP2018537517A (enExample)
KR (2) KR20240042148A (enExample)
CN (3) CN107614475A (enExample)
AU (3) AU2016327930B2 (enExample)
BR (1) BR112018005905B1 (enExample)
CA (2) CA2999368A1 (enExample)
EA (1) EA201890810A1 (enExample)
ES (1) ES3044383T3 (enExample)
HK (1) HK1244266A1 (enExample)
HR (1) HRP20250899T1 (enExample)
HU (1) HUE072982T2 (enExample)
MX (2) MX395231B (enExample)
MY (1) MY190647A (enExample)
PH (1) PH12018500659A1 (enExample)
SG (1) SG10202002573RA (enExample)
TW (1) TWI781912B (enExample)
WO (1) WO2017050298A1 (enExample)
ZA (1) ZA201802373B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520100A (ja) * 2013-11-13 2016-07-11 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
ES3044383T3 (en) 2015-09-24 2025-11-26 Sinew Pharma Inc Mannitol for use in treating hepatotoxicity and fatty liver diseases
TWI711464B (zh) * 2015-11-19 2020-12-01 欣耀生醫股份有限公司 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法
SG11202007314QA (en) * 2018-02-14 2020-08-28 Sinew Pharma Inc Methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (apap)
CN110538187A (zh) * 2018-05-28 2019-12-06 北京大学 Cpt1激活剂
KR102136326B1 (ko) * 2018-09-06 2020-07-22 서울대학교산학협력단 가시박으로부터 분리한 플라보노이드 유도체를 유효성분으로 포함하는 간 질환 예방 또는 치료용 조성물
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
AU2020211695A1 (en) * 2019-01-21 2021-09-02 National University Of Singapore Treatment of hepatotoxicity
CN110269855A (zh) * 2019-07-19 2019-09-24 辽宁大学 黄酮类小分子化合物在制备抑制胰脂肪酶活性药物中的应用
US12383191B1 (en) * 2020-05-04 2025-08-12 PathAI, Inc. Systems and methods for assessing liver pathology
CN113999272A (zh) * 2021-10-29 2022-02-01 广西医科大学 香蜂草苷的制备方法及其应用
CN113875982A (zh) * 2021-11-19 2022-01-04 武汉森澜生物科技有限公司 一种含二氢杨梅素的抗衰组合物及其应用
CN117482082A (zh) * 2023-11-27 2024-02-02 西北大学 金松双黄酮在制备抗慢性肾损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201515647A (zh) 2013-10-25 2015-05-01 Nat Defense Education And Res Foundation 無肝副作用之對乙醯胺基酚（Ａｃｅｔａｍｉｎｏｐｈｅｎ，ＡＰＡＰ）新複方組合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661519A (en) * 1983-04-12 1987-04-28 Pola Chemical Industries Inc. Method for dermatological application
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JP3916685B2 (ja) * 1996-02-29 2007-05-16 第一製薬株式会社 ガラクトース誘導体
JP4677550B2 (ja) * 2002-08-14 2011-04-27 独立行政法人産業技術総合研究所 環状エステル化合物
TWI287990B (en) * 2004-01-08 2007-10-11 Nat Defense Medical Ct Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B)
US20070009441A1 (en) * 2004-07-08 2007-01-11 Molecular Therapeutics, Inc. Biodegradable nanoparticles
CN1939929A (zh) * 2005-09-29 2007-04-04 云南白药集团股份有限公司 一种偏诺皂苷类化合物酸式盐及制备方法
CN108465110A (zh) * 2011-04-20 2018-08-31 教育研究基金会 无/低副作用的抗结核病药物复方
US20150291721A1 (en) * 2012-11-12 2015-10-15 Segetis, Inc. Crosslinkable polyketal esters, methods of manufacture and uses thereof
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
US9149491B2 (en) * 2013-04-29 2015-10-06 Harsha Chigurupati Reduced toxicity in alcoholic beverages
CN104623670A (zh) * 2013-11-06 2015-05-20 高松 一种含西红花素的组合物及其应用
JP2016520100A (ja) * 2013-11-13 2016-07-11 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN104292289B (zh) * 2014-07-10 2017-12-29 程怡 半乳糖配体及其在肝靶向脂质体中的应用
ES3044383T3 (en) * 2015-09-24 2025-11-26 Sinew Pharma Inc Mannitol for use in treating hepatotoxicity and fatty liver diseases
TWI711464B (zh) * 2015-11-19 2020-12-01 欣耀生醫股份有限公司 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201515647A (zh) 2013-10-25 2015-05-01 Nat Defense Education And Res Foundation 無肝副作用之對乙醯胺基酚（Ａｃｅｔａｍｉｎｏｐｈｅｎ，ＡＰＡＰ）新複方組合

Also Published As

Publication number Publication date
EP3991724A3 (en) 2022-07-27
MY190647A (en) 2022-04-30
HUE072982T2 (hu) 2025-12-28
BR112018005905A2 (pt) 2018-10-16
US20240335404A1 (en) 2024-10-10
PH12018500659A1 (en) 2018-10-01
KR20180058795A (ko) 2018-06-01
EA201890810A1 (ru) 2018-11-30
BR112018005905B1 (pt) 2023-03-21
CN107614475A (zh) 2018-01-19
EP3991724A2 (en) 2022-05-04
JP7261850B2 (ja) 2023-04-20
CN120398980A (zh) 2025-08-01
EP4609911A2 (en) 2025-09-03
ES3044383T3 (en) 2025-11-26
EP3991724C0 (en) 2025-07-16
WO2017050298A1 (en) 2017-03-30
US20200009097A1 (en) 2020-01-09
AU2024200963B2 (en) 2026-02-12
MX2018003700A (es) 2018-08-01
KR102891137B1 (ko) 2025-11-25
US20220265587A1 (en) 2022-08-25
HRP20250899T1 (hr) 2025-11-07
CA3232521A1 (en) 2017-03-30
HK1244266A1 (zh) 2018-08-03
TW201722897A (zh) 2017-07-01
MX2022007816A (es) 2022-08-02
CN120349362A (zh) 2025-07-22
AU2024200963A1 (en) 2024-03-07
AU2016327930B2 (en) 2021-04-15
KR20240042148A (ko) 2024-04-01
EP3353144A4 (en) 2019-06-05
AU2021205040B2 (en) 2023-11-16
JP2018537517A (ja) 2018-12-20
JP2022009680A (ja) 2022-01-14
AU2016327930A1 (en) 2018-05-10
EP3353144A1 (en) 2018-08-01
EP3991724B1 (en) 2025-07-16
CA2999368A1 (en) 2017-03-30
US20180256526A1 (en) 2018-09-13
EP4609911A3 (en) 2025-11-19
ZA201802373B (en) 2019-04-24
US10456371B2 (en) 2019-10-29
US11285123B2 (en) 2022-03-29
AU2021205040A1 (en) 2021-08-12
MX395231B (es) 2025-03-25
SG10202002573RA (en) 2020-05-28
US12083088B2 (en) 2024-09-10

Similar Documents

Publication Publication Date Title
JP7261850B2 (ja) 肝毒性および脂肪性肝疾患の処置に有効な化合物およびその使用
US10765660B2 (en) Agent containing flavonoid derivatives for treating cancer and inflammation
Lee et al. Determination of flavonoids from Cirsium japonicum var. maackii and their inhibitory activities against aldose reductase
US20090005438A1 (en) Use of Isothiocyanates Compounds in Treating Prostatic Diseases and Skin Cancer
US20140120181A1 (en) Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent
HK40131488A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
HK40128564A (zh) 有效於治疗肝毒性及脂肪肝疾病的化合物及其用途
HK40129564A (zh) 有效於治疗肝毒性及脂肪肝疾病的化合物及其用途
CN103420805A (zh) 天麻中具有神经细胞保护活性的多聚苄类衍生物
EA040650B1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CN114478464B (zh) 一种炎症小体选择性抑制剂及其合成方法和应用
CN114539204A (zh) 血脑屏障高通透性己糖激酶抑制剂及其合成方法和应用
CN110590838A (zh) Y27632前药、其制备方法及其在医药上的应用
HK1235284B (en) Compositions of selenoorganic compounds and methods of use thereof